Page 48 - AN-2-1

Advanced Neurology Piribedil for Parkinson’s disease

Table 2. (Continued)
Study, year Region Trial design Patients Treatment Primary Main results Evidence
outcome levela
Castro-Caldas Multi-national Multicenter, Patients with Piribedil Improvement of A 12-month I
et al., 2006 [38] randomized, stages I–III PD, (150 mg/day, n = 210) the UPDRS III treatment in
double-blind, poorly controlled or Bromocriptine score from baseline the piribedil or
controlled by levodopa (25 mg/day, n = 215) over 12 months, bromocriptine
clinical trial (n = 425) combined with expressed as the group may fully
levodopa change from improve motor
baseline to the last symptoms of
observed value, patients with
and second as PD, and the
the response rate dose increase
defined by a 30% or requirement of
more decrease on levodopa was less
the UPDRS III score in the piribedil
at the last value group
Xiao-ying et al., China Retrospective PD patients Compound levodopa NA The overall III
2016 [71] cohort study (n = 140) combined with effective rate
piribedil (100 – 150 in the piribedil
mg/day, n = 76); combined group
compound levodopa was significantly
monotherapy (n = 64) higher than that
in the control
group (92.10 vs.
62.50%, P < 0.05),
and the decrease
of UPDRS scores
was significantly
larger than that in
the control group
(P < 0.05)
Peihua and China and France Meta-analysis PD patients Piribedil combined NA The combination I
Jianqin, 2018 [34] involving 11 with levodopa therapy
studies (50~300 mg/day, group showed
n = 433); levodopa greater overall
monotherapy (NA) improvement of
response rate and
UPDRS scores
than levodopa
monotherapy
group
b
a The evidence’s levels were made with reference to the 2004 EFNS Guideline. Defined as at least 30% decrease from baseline of UPDRS III score.
NA: Not available; PD: Parkinson’s disease; UPDRS: Unified Parkinson’s disease rating scale.
for executive functions during the test. The WCST can further investigated by large-sample studies involving
recognize early cognitive impairments and has a good patients with PD [46,50] .
sensitivity to identify frontal cortical dysfunction. This
finding was more prominent in younger patients aged 50 3.2.3. Depression
– 70 years based on age stratification . Patients with depression show distinctly negative mood,
[38]
which causes emotional suffering.
Pilot clinical trials demonstrated that piribedil may
improve the frontal lobe dysfunction of patients with This is different from apathy, which is a mental
PD. Randomized, placebo-controlled, and double-blind disorder characterized by decreased goal-directed speech,
clinical trials also showed that patients with mild cognitive motor activity, and emotion. Patients with apathy have
[51]
disorder achieved some improvement in the overall indifference, but their mood is neutral .
cognitive function after receiving piribedil treatment Depression is the most common psychiatric non-motor
(63.3% vs. 26.7%, P < 0.01); however, this requires to be symptom in PD patients with a high prevalence rate of

Volume 2 Issue 1 (2023) 6 https://doi.org/10.36922/an.290